Stock Financial Ratios


RTIX / RTI Surgical, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.65
Volume111,200.00
Market Cap ($M)330.83
Enterprise Value ($M)334.65
Book Value ($M)164.92
Book Value / Share2.83
Price / Book1.80
NCAV ($M)309.07
NCAV / Share5.31
Price / NCAV1.17
Income Statement (mra) ($M)
Revenue272.87
EBITDA-15.68
Net Income-14.40
Balance Sheet (mrq) ($M)
Cash & Equivalents17.74
Cash / Share0.30
Assets353.28
Liabilities106.73
Quick Ratio1.03
Current Ratio3.06
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.06
Return on Assets (ROA)-0.04
Return on Equity (ROE)-0.09
Identifiers and Descriptors
CUSIP74975N105
Central Index Key (CIK)1100441
Industry Groups
SIC 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Other Related CUSIPS
74975N955
Share Statistics
Common Shares Outstanding (M)60.83
Scoring Models
Piotroski F Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Raw Materials Per Share0.00
Property Plant And Equipment Per Share1.42
Retained Earnings Per Share-3.94
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Liabilities Per Share1.83
Assets Non Current Per Share0.00
Assets Other Non Current Per Share0.03
Treasury Stock Per Share0.02
Liabilities Other Non Current Per Share0.04
Inventory Finished Goods Per Share0.85
Cash Per Share0.30
Liabilities Current Per Share0.93
Inventory Work In Progress Per Share0.00
Debt Per Share0.86
Liabilities And Stock Equity Per Share6.07
Goodwill Per Share0.79
Long Term Debt Per Share0.00
Equity Per Share3.15
Property Plant And Equipment Net Per Share1.42
Accounts Receivable Per Share0.62
Inventory Per Share1.97
Assets Per Share6.07
Accumulated Depreciation And Depletion Per Share1.23
Intangibles Per Share0.00
Additional Paid In Capital Per Share7.22
Minority Interest Per Share0.00
Assets Current Per Share3.09
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share2.65
Cash And Equivalents Per Share0.30

Related News Stories

Athersys' (ATHX) CEO Gil Van Bokkelen on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Good afternoon. My name is Erica and I will be your conference operator today. At this time, I would like to welcome everyone to the Athersys’ Third Quarter 2017 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. [Operator Instructions] Thank you. Ms. Laura Campbell, you may begin your conference. (45-0)

RTI Surgical's (RTIX) CEO Camille Farhat on Q3 2017 Results - Earnings Call Transcript

2017-11-02 seekingalpha
Good day, ladies and gentlemen, and welcome to the RTI Surgical's Third Quarter 2017 Earnings Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this call is being recorded. (5-0)

NuVasive's TLX Interbody System Gets Expanded FDA Approval

2017-10-19 zacks
NuVasive, Inc. (NUVA - Free Report) received an expanded 510(k) clearance from the FDA for its TLX interbody system. The TLX interbody system is inserted through a conventional transforaminal lumbar interbody fusion (TLIF) approach. TLX implants can be placed easily into the disc space due to their low profile, bulleted design. TLX is designed for a minimally-invasive spine surgery approach. (25-0)

NuVasive Acquires Vetera Spine, Grows With Spinal Hardware

2017-09-28 zacks
Per a Sep 18 article published on Duke University website, NuVasive, Inc. (NUVA - Free Report) has reportedly closed another acquisition. This time, it is a start-up company called Vertera Spine, created through research at both Duke University and the Georgia Institute of Technology. However, financial terms of the deal have not been disclosed. (25-0)

Athersys' (ATHX) CEO Gil Van Bokkelen on Q2 2017 Results - Earnings Call Transcript

2017-08-10 seekingalpha
Good afternoon. My name is Jesse, and I'll be your conference operator today. At this time, I would like to welcome everyone to Athersys' Second Quarter 2017 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.

CUSIP: 74975N105